Nektar Therapeutics (NKTR)
$39.84-3.23%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $779M
- Beta
- 1.15
- P/E (TTM)
- -5.96
- Short % float
- 38.02%
- Days to cover
- 3.8
- SI change
- +21.5%
- 1W
- -5.64%
- 1M
- -42.89%
- vs SPY 1W
- -6.06%
- vs SPY 1M
- -44.95%
Industry peers
FMP comparable companies · ranked by market cap
- RCUSSELLArcus Biosciences, Inc.$3.1BRECOVERYQ 17$24.28-0.29%
- XNCRSELLXencor, Inc.$1.8BRECOVERYQ 16$24.36+1.66%
- IMCRSELLImmunocore Holdings plc$1.5BBEARQ 2$29.55-1.19%
- IMTXSELLImmatics N.V.$1.0BCRISISQ 6$7.50-2.96%
- CRVSSELLCorvus Pharmaceuticals, Inc.$888MCRISISQ 13$10.56-4.47%
- ANLSELLAdlai Nortye Ltd.$768MCRISISQ 14$14.46-8.96%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NKTR?
- LOPJLB’s latest quantitative signal on Nektar Therapeutics (NKTR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NKTR in?
- Nektar Therapeutics (NKTR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Nektar Therapeutics (NKTR) do?
- Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder ca…